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We hypothesized that the fundamental role of nitric oxide
and cyclic GMP in numerous physiological processes
would suggest that these mediators also participate in
stem cell proliferation and differentiation. Mouse and
human (H9) embryonic stem cells were cultured under
standard conditions for various periods (one to 15 days).
The hanging drop method was utilized to induce differen-
tiation of stem cells into various cellular lineages includ-
ing myocardial, neuronal precursor, neuronal, astrocyte
and oligodendrocytes.
As determined by QT-PCR and Western immunoblots
NOS-1 was elevated at day 1 and diminished over 7 to 12
days of culture. In contrast, NOS-2, NOS-3, and α and β
subunits of soluble guanylyl cyclase and PKG were low at
day one and progressively increased with proliferation
and differentiation. The localization of these proteins
could be found in myocardial cells, neural precursor cells,
neural cells and glial cells with immunofluorescence (his-
tochemistry and FACS) using colocalization with cell spe-
cific markers.
Under some conditions addition of ODQ, the soluble
guanylyl cyclase inhibitor, increased the differentiation of
stem cells into myocardial cells and decreased the differ-
entiation into neural and glial cells. Addition of cyclic
GMP analogues could overcome the ODQ effect with
myocardial differentiation.
These studies support our hypothesis that NO and cyclic
GMP influence stem cell proliferation and differentiation.
Other studies with pharmacologic and/or genetic manip-
ulation of these stem cells are in progress.
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